Watchdog Warns Psychiatry Resists Federal Antidepressant Deprescribing Initiatives, Citing Patient Safety

The mental health industry watchdog, Citizens Commission on Human Rights International (CCHR), warns that organized psychiatry's historical pattern of downplaying psychiatric drug risks could undermine the Department of Health and Human Services' (HHS) May 2026 plan for safe antidepressant deprescribing. CCHR urges federal officials to implement even stronger protections for informed consent and patient safety, aligning with international concerns like the 2024 UK All-Party Parliamentary Group report on antidepressant deprescribing and withdrawal support.

CCHR highlights instances of alleged resistance, including a 2025 psychiatric committee's selective survey, where 94% of respondents disagreed with HHS reforms. This echoes past opposition, such as a prominent psychiatrist's formal objection to an FDA Black Box warning on SSRI antidepressants in 2004, citing concerns about a "chilling effect" on prescribing despite numerous suicide cases. CCHR views current resistance as a move to protect antidepressant prescribing, given psychiatry's past financial ties and the debunked "chemical imbalance" theory, which was promoted despite scientific evidence to the contrary.

Historically, psychiatric organizations have also consistently minimized withdrawal risks, often misdiagnosing severe symptoms as relapse. CCHR President Jan Eastgate emphasizes that psychiatry's decades-long pattern of downplaying risks, opposing warnings, and maintaining pharmaceutical relationships undermines claims of genuine support for the current Administration's deprescribing efforts. CCHR urges full implementation of the HHS plan with robust safeguards for informed consent and comprehensive deprescribing support to prioritize patient well-being over unchecked prescribing.